Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_assertion type Assertion NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_head.
- NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_assertion description "[The high prevalence of the silencing of RELN pathway components and its reversal by histone deacetylase inhibitors suggest the importance of this pathway as a diagnostic and therapeutic target for pancreatic cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_provenance.
- NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_assertion evidence source_evidence_literature NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_provenance.
- NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_assertion SIO_000772 16472607 NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_provenance.
- NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_assertion wasDerivedFrom befree-2016 NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_provenance.
- NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_assertion wasGeneratedBy ECO_0000203 NP535512.RARVukDdmN93f8bFHeOhraMDa73GlOkqvgdHs4Ey-k_NU130_provenance.